Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8- Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild- type and mutant enzymes

Journal of Medicinal Chemistry

Volumn 41, Issue 16, 1998, Pages 2960-2971

  Klunder, Janice M ^a,b   Hoermann, MaryAnn ^a   Cywin, Charles L ^a   David, Eva ^a   Brickwood, Janice R ^a   Schwartz, Racheline ^a   Barringer, Kevin J ^d   Pauletti, Daniel ^a   Shih, Cheng Kon ^a   Erickson, David A ^a   Sorge, Christopher L ^a   Joseph, David P ^a   Hattox, Susan E ^a   Adams, Julian ^a,c   Grob, Peter M ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b WILMER CUTLER PICKERING HALE AND DORR LLP   (United States)

^c ProScript Inc   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYSTEINE; MUTANT PROTEIN; NEVIRAPINE; PYRIDODIAZEPINONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; AZEPINES; CELL LINE, TRANSFORMED; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROSOMES, LIVER; MUTATION; NEVIRAPINE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 14444278761     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9707028     Document Type: Article

References (43)

1. (a) Kempf D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm Res. 1996, 2, 225-246.
2. (b) Deeks, S. G.; Smith, M.; Holdniy, M.; Kahn J. O. HIV-1 Protease Inhibitors. A Review for Clinicians. J. Am. Med. Assoc. 1997, 277, 145-153.
3. (c) Lewis, J. S. 2nd Protease Inhibitors: A Therapeutic Breakthrough for the Treatment of Patients with Human Immunodeficiency Virus. Clin. Ther. 1997, 19, 187-214.
4. (a) Saunders: J.; Storer, R. New Developments in RT Inhibitors. Drug News Perspect. 1992, 5, 153-169.
5. (b) Tucker, T. J.; Lumma, W. C.; Culberson, J. C. Development of Nonnucleoside HIV Reverse Transcriptase Inhibitors. Methods Enzymol. 1996, 275, 440-472.
6. (c) Balzarini, J.; De Clercq, E. Methods Enzymol. 1996, 275, 472-502.
7. Richman, D. D. Antiretroviral Drug Resistance: Mechanisms, Pathogenesis, Clinical Significance. Adv. Exp. Med. Biol. 1996, 394, 383-395.
8. For general reviews, see: (a) Collier, A. C. Efficacy of Combination Antiretroviral Therapy. Adv. Exp. Med. Biol. 1996, 394, 355-372. (b) Vella, S.; Franca Pirillo, M. Combination Therapy in the Management of HIV Infection. Methods Find. Exp. Clin. Pharm. 1996, 18 (Suppl. C), 23-26.
9. For general reviews, see: (a) Collier, A. C. Efficacy of Combination Antiretroviral Therapy. Adv. Exp. Med. Biol. 1996, 394, 355-372. (b) Vella, S.; Franca Pirillo, M. Combination Therapy in the Management of HIV Infection. Methods Find. Exp. Clin. Pharm. 1996, 18 (Suppl. C), 23-26.
10. For clinical trials involving nevirapine, see: (a) Carr, A.; Cooper, D. A. Current Clinical Experience with Nevirapine for HIV Infection. Adv. Exp. Med. Biol. 1996, 394. (b) Luzuriaga, K.; Bryson, Y.; Krostad, P.; Robinson, J.; Stechenberg, B.; Lamson, M.; Cort, S.; Sullivan, J. L. Combination Treatment with Zidovudine, Didanosine, and Nevirapine in Infants with Human Immunodeficiency Virus Type 1 Infection. N. Engl J. Med. 1997, 336, 1343-1349. D'Aquila, R. T.; Hughes, M. D.; Johnson, V. A.; Fischl, M. A.; Sommadossi, J.-P.; Liou, S.; Timpone, J.; Myers, M.; Basgoz, N.; Niu, M.; Hirsch, M. S.; and the National Institute of Allergy and Infections Diseases AIDS Clinical Trials Group 241 Investigators. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection. Ann. Int. Med. 1996, 124, 1019-1030.
11. For clinical trials involving nevirapine, see: (a) Carr, A.; Cooper, D. A. Current Clinical Experience with Nevirapine for HIV Infection. Adv. Exp. Med. Biol. 1996, 394. (b) Luzuriaga, K.; Bryson, Y.; Krostad, P.; Robinson, J.; Stechenberg, B.; Lamson, M.; Cort, S.; Sullivan, J. L. Combination Treatment with Zidovudine, Didanosine, and Nevirapine in Infants with Human Immunodeficiency Virus Type 1 Infection. N. Engl J. Med. 1997, 336, 1343-1349. D'Aquila, R. T.; Hughes, M. D.; Johnson, V. A.; Fischl, M. A.; Sommadossi, J.-P.; Liou, S.; Timpone, J.; Myers, M.; Basgoz, N.; Niu, M.; Hirsch, M. S.; and the National Institute of Allergy and Infections Diseases AIDS Clinical Trials Group 241 Investigators. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection. Ann. Int. Med. 1996, 124, 1019-1030.
12. For clinical trials involving nevirapine, see: (a) Carr, A.; Cooper, D. A. Current Clinical Experience with Nevirapine for HIV Infection. Adv. Exp. Med. Biol. 1996, 394. (b) Luzuriaga, K.; Bryson, Y.; Krostad, P.; Robinson, J.; Stechenberg, B.; Lamson, M.; Cort, S.; Sullivan, J. L. Combination Treatment with Zidovudine, Didanosine, and Nevirapine in Infants with Human Immunodeficiency Virus Type 1 Infection. N. Engl J. Med. 1997, 336, 1343-1349. (c) D'Aquila, R. T.; Hughes, M. D.; Johnson, V. A.; Fischl, M. A.; Sommadossi, J.-P.; Liou, S.; Timpone, J.; Myers, M.; Basgoz, N.; Niu, M.; Hirsch, M. S.; and the National Institute of Allergy and Infections Diseases AIDS Clinical Trials Group 241 Investigators. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection. Ann. Int. Med. 1996, 124, 1019-1030.
13. (a) Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 Replication by a Non-Nucleoside Reverse Transcriptase Inhibitor. Science 1990, 250, 1411-1413
14. (b) Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J. Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231-2241.
15. (a) Richman, D.; Shih, C.-K.; Lowy, I.; Rose, J.; Prodanovich, P.; Goff, S.; Griffin, J. Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors Of Reverse Transcriptase Arise In Tissue Culture. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11241-11245.
16. (b) Richman, D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S. A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D.; Shih, C.-K.; Myers, M.; Griffin, J. Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected During Therapy. J. Virol. 1994, 68, 1660-1666.
17. de Clercq, E. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) for the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections: Strategies to Overcome Drug Resistance Development. Med. Res. Rev. 1996, 16, 125.
18. (a) Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice P. A.; Steitz, T. A. Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed With An Inhibitor. Science 1992, 256, 1783-1790.
19. (b) Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the Binding Site for Non-nucleoside Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
20. (c) Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors. Struct. Biol. 1995, 2, 303-308.
21. Larder, B. A.; Purifoy, D. J. M.; Powell, K. L.; Darby, G. Site-specific Mutagenesis of AIDS Virus Reverse Transcriptase. Nature 1987, 327, 716.
22. (a) Proudfoot, J. R.; Hargrave, K. D.; Kapadia, S. R.; Patel, U. R.; Grozinger, K. G.; McNeil, D. W.; Cullen, E.; Cardozo, M.; Tong, L.; Kelly, T. A.; Rose, J.; David, E.; Mauldin, S. C.; Fuchs, V. U.; Vitous, J.; Hoermann, M.; Klunder, J. M.; Raghavan, P.; Skiles, J. W.; Mui, P.; Richman, D. D.; Sullivan, J. L.; Shih, C.-K.; Grob, P. M.; Adams, J. Novel Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes. J. Med. Chem. 1995, 38, 4830-4838.
23. (b) Kelly, T. A.; McNeil, D. W.; Rose, J. M.; David, E.; Shih, C.-K.; Grob, P. M Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 6. 2-Indol-3-yl and 2-azaindol-3-yl Dipyridodiazepinones. J. Med. Chem. 1997, 40, 2430-2433.
24. Cywin, C. L.; Klunder, J. M.; Hoermann, M.; Brickwood, J. R.; David, E.; Grob, P. M.; Schwartz, R.; Pauletti, D.; Barringer, K. J.; Shih, C.-K.; Sorge, C. L.; Erickson, D. A.; Joseph, D. P.; Hattox, S. E. Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones. J. Med. Chem. 1998, 41, 2972-2984.
25. Stille, J. K. The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
26. (a) Negishi, E. Palladium- or Nickel-Catalyzed Cross-Coupling. A New Selective Method for Carbon-Carbon Bond Formation. Acc. Chem. Res. 1982, 15, 340-348.
27. (b) Sakamoto, T. Nishimura, S.; Kondo, Y.; Yamanaka, H. Palladium-Catalyzed Coupling Reaction of N-Heteroaryl Halides with Functionalized Alkylzinc Iodides. Synthesis 1988, 485-486.
28. Heck R. F. Palladium Catalyzed Reactions of Organic Halides with Olefins. Acc. Chem. Res. 1979, 12, 146-151.
29. Johnstone, R. A. W.; Wilby, A. H.; Entwistle, I. D. Heterogeneous Catalytic Transfer Hydrogenation and Its Relation to Other Methods for Reduction of Organic Compounds. Chem. Rev. 1985, 85, 129-170.
30. Entwistle, I. D.; Jackson, A. E.; Johnstone, R. A. W.; Telford, R. P. Reduction of Nitro-compounds. J. Chem. Soc., Perkin Trans. 1 1977, 443-444.
31. Dalton, J. R.; Regen, S. L. Alumina-Assisted Aryl Cyanation. J. Org. Chem. 1979, 44, 4443-4444.
32. Aoyagi, Y.; Inoue, A.; Koizumi, I.; Hashimoto, R.; Tokunaga, K.; Gohma, K.; Komatsu, J.; Sekine, K.; Miyafuji, A.; Kunoh, J.; Honma, R.; Akita, Y.; Ohta, A. Paladium-Catalyzed Cross-Coupling Reactions of Chloropyrazines with Aromatic Heterocycles. Heterocycles 1992, 33, 257-272.
33. Oae, S.; Ogino, K. Rearrangements of t-Amine Oxides. Hetorocycles 1977, 6, 583.
34. Ashimori, A.; Ono, T.; Uchida, T.; Ohtaki, Y.; Fukaya C.; Watanabe, M.; Yokoyama, K. Novel 1,4-Dihydropyridine Calcium Antagonists. I. Synthesis and Hypotensive Activity of 4-(Substituted pyridyl)-1,4-dihydropyridine Derivatives. Chem. Pharm. Bull. 1990, 38, 2446.
35. Klunder, J. M.; Hargrave, K. D.; West, M.; Cullen, E.; Pal, K.; Behnke, M. L.; Kapadia, S. R.; McNeil, D. W.; Wu, J. C.; Chow, G. C.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones. J. Med. Chem. 1992, 35, 1887-1897.
36. Dueweke, T. J.; Pushkarskaya, T.; Poppe, S. M.; Swaney, S. M.; Zhao, J. Q.; Chen, I. S. Y.; Stevenson, M.; Tarpley, W. G. A Mutation in Reverse Transcriptase of Bis(heteroaryl)piperazine-resistant Human Immunodeficiency Virus Type 1That Confers Increased Sensitivity to Other Nonnucleoside Inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4713.
37. Nunberg, J. H.; Schleif, W. A.; Boots, E. J.; O'Brien, J. A.; Quintero, J. C.; Hoffman, J. M.; Emini, E. A.; Goldman, M. E. Viral resistance to Human Immunodeficiency Virus Type 1-specific Pyridinone Reverse Transcriptase Inhibitors. J. Virol. 1991, 65, 4887-4892.
38. Tong, L.; Cardozo, M.; Jones, P.-J.; Adams, J. Preliminary Structural Analysis of the Mutations Selected by Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Bioorg. Med. Chem. Lett. 1993, 3, 721-726.
39. The time and number of passages required for isolation of resistant virus varied from experiment to experiment, but was only modestly increased relative to nevirapine. Shih, C.-K.; Schwartz, R.; Barringer, K. Unpublished results.
40. (a) Powis, G.; Jardine, I.; Van Dyke, R.; Weishilboum, R.; Moore, D.; Wilke, T.; Rhodes, W.; Nelson, R.; Benson, L.; Szumlanski, C. Foreign Compound Metabolism Studies With Human Liver Obtained as Surgical Waste, Relation To Donor Characteristics And Effects Of Tissue Storage. Drug Metab. Dispos. 1988, 16, 582-589.
41. (b) details of assay are reported in ref 12.
42. Shih, C.-K.; Brickwood, J. R. Unpublished results.
43. Regen, S. L.; Wuici, S.; Liaw, S.-J. Impregnated Cyanide Reagents. Convenient Synthesis of Nitriles. J. Org. Chem. 1979, 44, 2029-2030.